Viatris Report issue

For profit Phase 2 Phase 4
Founded: Nottingham United Kingdom (1993)
Status: Acquired by Meda Pharmaceuticals (2005) → now Mylan (2016)

Organization Overview

First Clinical Trial
2021
NCT05319756
First Marketed Drug
1993
phenytoin (mesantoin)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Investigational drug(Pretomanid) supported by Viatris Pharmaceutical | VIATRIS | Viatris Inc. | Viatris Specialty LLC

Active Ingredients

Marketed Drugs (8)

amlodipine (norvasc) (1992)

doxazosin (cardura) (1990)

gabapentin (neurontin) (1993)

nitroglycerin (transderm-nitro) (2000)

phenytoin (mesantoin) (1953)

sertraline (zoloft) (1991)

sildenafil (viagra) (1998)

ziprasidone (geodon) (2001)

Drugs in Phase 4 Trials (3)

Key: Viatris (2) Acquired (1)

gabapentin (neurontin) (1 trial)

oxycodone (oxycontin) (1 trial)

varenicline (chantix) (10 trials)

Drugs in Phase 2 Trials (1)

Key: Viatris (0) Acquired (1)

simpanicline (2 trials)

Indications

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial APIs: 4